Key result
Tranexamic acid (RR -3.46; 95% CI -7.63 to -0.77), N-butyl-2-cyanoacrylate, and calcium sulfate decreased bleeding events compared to placebo in dental patients on oral anticoagulation.
Why the study?
The study was conducted to determine the effectiveness of hemostatic protocols to prevent bleeding in dental procedures among individuals undergoing oral anticoagulation therapy.
Do local hemostatic agents prevent bleeding in dental patients on oral anticoagulation?
Meta-Analysis
Do local hemostatic agents prevent bleeding in dental patients on oral anticoagulation?
Relative Risk: -3.46 (95% CI -7.63–-0.77)
Tranexamic acid is an effective local hemostatic agent with moderate certainty evidence for preventing bleeding in anticoagulated patients undergoing dental procedures.
Supports tranexamic acid use to reduce bleeding in anticoagulated dental patients; reinforces moderate-certainty evidence for local hemostatics.
This study aimed to determine the effectiveness of hemostatic protocols to prevent bleeding in dental procedures among individuals undergoing oral anticoagulation therapy. A systematic review and network meta-analysis were accomplished. Searches of literature and grey literature were performed in different electronic databases. Clinical trials were considered as part of the inclusion criteria. Data extraction and assessment of the risk of bias of the included articles were performed. Assessment of the certainty of evidence was also performed. As results we find that the N-butyl-2-cyanoacrylate [RR -35.00 (95% CI - 107.12, −5.78)], calcium sulfate (CaSO4) [RR -5.62 (95% CI -11.41, −1.03)], and tranexamic acid (TXA) [RR -3.46 (95% CI -7.63, −0.77)] showed beneficial effects compared to placebo. However, only TXA presented beneficial effects with moderate certainty evidence. N-butyl-2-cyanoacrylate and CaSO4 presented very low certainty evidence. In the comparisons between the hemostatic agents, no differences were observed. For the mean bleeding time, no significant difference in the comparisons was observed as well. Concluding, bleeding events in individuals on oral anticoagulation decreased with the use of TXA compared to placebo. N-butyl-2-cyanoacrylate and CaSO4 were also superior to placebo, but the certainty of evidence was low. For the mean bleeding time, no significant difference in hemostatic agents was observed.
No takes yet. Share an insight, caveat, or question.
Moreno-Drada et al. (2021) conducted a meta-analysis in Dental patients on oral anticoagulation therapy. Tranexamic acid (TXA) vs. Placebo was evaluated on Bleeding events (RR -3.46, 95% CI -7.63, -0.77). Tranexamic acid (RR -3.46; 95% CI -7.63 to -0.77), N-butyl-2-cyanoacrylate, and calcium sulfate decreased bleeding events compared to placebo in dental patients on oral anticoagulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: